Physician profile
Travis Carroll
NPI 1255868295
$1,191.53
in general payments reported to CMS, 2019-2025
18 companies · $908 in 2025
The $908 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $283 · 2025: $908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,191.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $338.08 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $235.38 | 2024-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $153.36 | 2024-2025 | |
| Novo Nordisk INC | $63.13 | 2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.42 | 2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $61.85 | 2025 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $42.19 | 2024-2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $34.16 | 2024-2025 | Verquvo |
| Philips North America LLC | $30.19 | 2025 | Mcot, Ambulatory Monitoring & Diagnostics Undivided |
| Scpharmaceuticals INC. | $28.02 | 2024 | |
| Daiichi Sankyo INC. | $22.21 | 2025 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $21.81 | 2024 | |
| Boston Scientific Corporation | $19.38 | 2025 | Watchman Flx |
| Bridgebio Pharma, INC. | $18.28 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $17.50 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $15.38 | 2024 | |
| Amgen INC. | $14.23 | 2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $13.96 | 2025 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.